Instil Bio CEO and leadership

Robert Hawkins is Chief Strategy Advisor at Instil Bio a Cell Therapy Company. His aim is to develop effective adoptive cell therapies for solid tumours. Prior to the acquisition of Immetacyte Ltd by Instil Bio Inc in March 2020, he was CEO of Immetacyte. He founded Immetacyte as a cell therapy spinout from the University of Manchester.

Prior to that he was Cancer Research UK Professor of Medical Oncology at the University of Manchester and Christie Hospital. His main clinical specialty is the treatment of metastatic renal cancer. He is also an expert in pre-clinical and clinical development of antibodies, gene therapy, cell therapy and cancer immunotherapy.

Dr. Roberts is a board certified oncologist and immunologist with extensive experience in clinical oncology and oncology drug and cell therapy development. Prior to joining Instil, Dr. Roberts held various roles of increasing responsibility at Kite Pharma (acquired by Gilead in 2017) where he led the development of both clinical and near-clinical cell therapy assets, established several strategic domestic and international corporate partnerships, and held key scientific advisory and oversight roles within the company. Before joining Kite, Dr. Roberts led several solid tumor studies at Amgen. He holds an MD and PhD in immunology from the University of Maryland, Baltimore, where he graduated magna cum laude from both medical and graduate schools. He went on to complete his clinical and post-doctoral training at Massachusetts General Hospital and the Dana-Farber Cancer Institute.

Dr. Laumas currently serves as the Chief Business Officer and Chief Financial Officer of Instil Bio, Inc. Prior to joining Instil Bio, Dr. Laumas has been actively involved in healthcare investing and serving on company Boards of Directors. He currently serves as a member of the board of directors of BioXcel Therapeutics, Inc. and 9 Meters Biopharma, Inc. He began his career at Goldman Sachs & Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. He has been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr. Laumas has served as a director of Parkway Holdings Ltd. (IHH Healthcare) and SRL Ltd. He has a unique industry perspective, particularly in both public and private investments and financial transactions in the healthcare arena. Dr. Laumas received his A.B. in chemistry from Cornell University in 1990, his M.D. from Albany Medical College, with a research year at the Dana-Farber Cancer Institute, and completed his medical internship at the Yale University School of Medicine.

Vijay Chiruvolu is a Chief Technical Officer at Instil Bio and is based in Los Angeles, California.

Robert Hawkins is Chief Strategy Advisor at Instil Bio a Cell Therapy Company. His aim is to develop effective adoptive cell therapies for solid tumours. Prior to the acquisition of Immetacyte Ltd by Instil Bio Inc in March 2020, he was CEO of Immetacyte. He founded Immetacyte as a cell therapy spinout from the University of Manchester.

Prior to that he was Cancer Research UK Professor of Medical Oncology at the University of Manchester and Christie Hospital. His main clinical specialty is the treatment of metastatic renal cancer. He is also an expert in pre-clinical and clinical development of antibodies, gene therapy, cell therapy and cancer immunotherapy.

Robert Hawkins is Chief Strategy Advisor at Instil Bio a Cell Therapy Company. His aim is to develop effective adoptive cell therapies for solid tumours. Prior to the acquisition of Immetacyte Ltd by Instil Bio Inc in March 2020, he was CEO of Immetacyte. He founded Immetacyte as a cell therapy spinout from the University of Manchester.

Prior to that he was Cancer Research UK Professor of Medical Oncology at the University of Manchester and Christie Hospital. His main clinical specialty is the treatment of metastatic renal cancer. He is also an expert in pre-clinical and clinical development of antibodies, gene therapy, cell therapy and cancer immunotherapy.

Vijay Chiruvolu is a Chief Technical Officer at Instil Bio and is based in Los Angeles, California.